1304. Trends in antimicrobial susceptibility of Neisseria gonorrhea in a sexually transmitted disease (STD) clinic in central Israel, 2009 to 2014
Session: Poster Abstract Session: Clinical Infectious Diseases: Sexually Transmitted Infections
Friday, October 28, 2016
Room: Poster Hall
Posters
  • Gonorrhea ID week 2016 poster.pdf (698.0 kB)
  • Background: We assessed antibiotic susceptibility to all N. gonorrhea isolates from patients attending a walk in STD clinic during 1.2009-7.2014.

    Methods: Strains were isolated from clinical and screening specimens. Susceptibility to penicillin, ceftriaxone, tetracycline, ciprofloxacin azithromycin and spectinomycin was performed using Etests. Gentamicin susceptibility by Etest was performed since 2011. EUCAST criteria were used to define breakpoints. We calculated geometrical MIC means. ANOVA was used for comparisons.

    Results: 338 isolates were tested. Mean age was 34. Samples were taken from urethral discharge 190 (56.2%), pharynx 130 (38.5%) and rectum (5.3%). See table for antibiotic susceptibility (year, % sensitive/resistant). All isolates remained susceptible to ceftriaxone. There was significant decline in susceptibility for tetracycline and azithromycin. All isolates were sensitive to spectinomycin, but there was a significant rise in MICs within the susceptible range. None had MIC>8mg/l for gentamycin but a significant trend towards higher MICs was noted. Ciprofloxacin susceptibility remained ~50%.

    Conclusion: Rate of susceptible isolates to tetracycline, and azithromycin decreased significantly since 2013. MICs are also increasing within the susceptible range for tetracycline, azithromycin, spectinomycin and gentamicin. This emphasizes the importance of surveillance.

    Penicillin

    N=338

    Ceftriaxone

    N=338

    Tetracycline*

    N=3382009

    Ciprofloxacin

    N=338

    Azithromycin*

    N=337

    Spectinomycin*

    N=338

    Gentamicin*

    N=115

    2009

    0.358

    4.2/14.6

    0.008

    100/0

    0.817

    60.4/25.0

    0.140

    50.0/50.0

    0.233

    81.2/10.4

    8.813

    100/0

    -
    2010

    0.417

    13.3/16.7

    0.006

    100/0

    0.880

    66.7/20.0

    0.163

    46.7/53.3

    0.183

    93.3/0

    7.972

    100/0

    -
    2011

    0.244

    14.3/14.3

    0.005

    100/0

    0.806

    83.9/3.6

    0.020

    75.0/25.0

    0.224

    98.2/0

    8.540

    100/0

    3.984

    -

    2012

    0.266

    15.8/13.2

    0.005

    100/0

    0.570

    81.6/15.8

    0.068

    61.8/38.2

    0.180

    94.7/0

    7.942

    100/0

    3.932

    -

    2013

    0.470

    2.3/18.6

    0.005

    100/0

    1.483

    59.3/36.0

    0.125

    54.7/45.3

    0.265

    72.1/5.8

    10.567

    100/0

    5.499

    -

    2004

    0.479

    7.1/14.3

    0.006

    100/0

    4.356

    35.7/54.8

    0.570

    35.7/64.3

    0.240

    3.8/0

    12.325

    100/0

    6.397

    -

    MIC geomtric means, % suceptible/resistant. *P<0.05

     

    Yasmin Maor, MD1,2, Orit Yossepowitch, MD1, Orna Schwartz, Ms1, Yael Goor, MsW3, Rivka Sheffer, MD2,3, Michael Dan, MD2 and Tamar Gottesman, MD1, (1)Wolfson Medical Center, Holon, Israel, (2)Tel Aviv University, Tel Aviv, Israel, (3)Tel Aviv District Health Office, Tel Aviv, Israel

    Disclosures:

    Y. Maor, None

    O. Yossepowitch, None

    O. Schwartz, None

    Y. Goor, None

    R. Sheffer, None

    M. Dan, None

    T. Gottesman, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.